Skip to main content


We're creating a new version of this page. See preview

  • Hypothesis
  • Open Access

Possible use of repeated cold stress for reducing fatigue in Chronic Fatigue Syndrome: a hypothesis

Behavioral and Brain Functions20073:55

  • Received: 05 July 2007
  • Accepted: 24 October 2007
  • Published:



Physiological fatigue can be defined as a reduction in the force output and/or energy-generating capacity of skeletal muscle after exertion, which may manifest itself as an inability to continue exercise or usual activities at the same intensity. A typical example of a fatigue-related disorder is chronic fatigue syndrome (CFS), a disabling condition of unknown etiology and with uncertain therapeutic options. Recent advances in elucidating pathophysiology of this disorder revealed hypofunction of the hypothalamic-pituitary-adrenal axis and that fatigue in CFS patients appears to be associated with reduced motor neurotransmission in the central nervous system (CNS) and to a smaller extent with increased fatigability of skeletal muscle. There is also some limited evidence that CFS patients may have excessive serotonergic activity in the brain and low opioid tone.

Presentation of the hypothesis

This work hypothesizes that repeated cold stress may reduce fatigue in CFS because brief exposure to cold may transiently reverse some physiological changes associated with this illness. For example, exposure to cold can activate components of the reticular activating system such as raphe nuclei and locus ceruleus, which can result in activation of behavior and increased capacity of the CNS to recruit motoneurons. Cold stress has also been shown to reduce the level of serotonin in most regions of the brain (except brainstem), which would be consistent with reduced fatigue according to animal models of exercise-related fatigue. Finally, exposure to cold increases metabolic rate and transiently activates the hypothalamic-pituitary-adrenal axis as evidenced by a temporary increase in the plasma levels of adrenocorticotropic hormone, beta-endorphin and a modest increase in cortisol. The increased opioid tone and high metabolic rate could diminish fatigue by reducing muscle pain and accelerating recovery of fatigued muscle, respectively.

Testing the hypothesis

To test the hypothesis, a treatment is proposed that consists of adapted cold showers (20 degrees Celsius, 3 minutes, preceded by a 5-minute gradual adaptation to make the procedure more comfortable) used twice daily.

Implications of the hypothesis

If testing supports the proposed hypothesis, this could advance our understanding of the mechanisms of fatigue in CFS.


  • Cold Stress
  • Chronic Fatigue Syndrome
  • Chronic Fatigue Syndrome Patient
  • Contrary Evidence
  • Autonomic Nervous System Dysfunction


There seems to be no universally accepted definition of biological fatigue [1], although it is often defined as a reduction in the force output and/or energy-generating capacity of skeletal muscle after exertion, which may manifest itself as an inability to continue exercise or usual activities at the same intensity [14]. Fatigue is thought to be associated with a diminished contractile ability of muscles due to accumulation of lactic acid and depletion of energy stores (glycogen) [5, 6] as well as with a reduction in motor neurotransmission delivered to skeletal muscle by the central nervous system (CNS), all of which can result in diminished force output [7, 8]. At the level of the CNS, precise mechanisms of fatigue are not well understood, although there is some evidence that it may be associated with diminished activity of a brainstem structure called reticular activating system [911] and with increased levels of serotonin in the frontal cortex and hippocampus [12, 13].

A typical fatigue-related disorder is chronic fatigue syndrome (CFS), a complex and disabling condition characterized by extended periods of severe fatigue unexplained by known medical causes [14]. Currently, there are no specific diagnostic tests and etiology of CFS remains elusive, although some progress has been made in elucidating its pathophysiology [15, 16]. A number of studies have reported insufficient function of the hypothalamic-pituitary-adrenal (HPA) axis (e.g. lowered production of cortisol [16, 17]) and a rather frequent occurrence of autonomic nervous system dysfunction in patients with CFS [16, 18]. Neither lowered production of cortisol nor dysautonomia appears to be a causative factor in most CFS patients because cortisol injections and various therapeutic approaches to autonomic nervous system abnormalities have so far shown a rather limited effect on CFS symptoms [17, 19, 20]. Other findings about the pathophysiology of CFS suggest that abnormal fatigability in this disorder is associated with a reduced ability of the CNS to recruit motor neurons [2123] and with some biochemical abnormalities in skeletal muscle [2426]. In addition, there is some evidence that CFS patients may have a low opioid tone ([2730], contrary evidence: [31, 32]), as well as an increased level of serotonergic activity in the brain ([3338], contrary evidence: [39, 40]). The latter has been shown to correlate with fatigue in animal models of exercise-related fatigue [13, 4145].

This paper describes a physiological treatment, namely, exposure to moderate cold, which could have a beneficial effect on some of the above-mentioned pathological changes as explained in more detail below.

Presentation of the hypothesis

It is known that small amounts of stressful or harmful agents can be beneficial for animals, a phenomenon known as hormesis [46, 47]. In particular, exposure to cold can transiently reverse several physiological changes that are often associated with CFS and therefore, the hypothesis is that repeated cold stress can reduce fatigue in CFS patients. The following is detailed theoretical evidence that appears to support this hypothesis.
  1. 1)

    Insufficient function of the HPA axis has been found to correlate with fatigue [48], for example, a lowered plasma level of stress hormone cortisol (secreted by adrenal glands) is one of the few consistent endocrine changes found in CFS in numerous studies [17], although the level of cortisol in CFS patients is within the normal range and therefore cannot be used as a diagnostic tool [16]. Cold stress is known to transiently activate the HPA axis [49, 50] as evidenced by a brief increase in the plasma levels of adrenocorticotropic hormone [51, 52] and beta-endorphin (the latter is a secreted by the pituitary gland) [53, 54], as well as a modest elevation in the level of cortisol [55, 56]. Some studies reported no significant change in cortisol levels following cold stress [57, 58], which may be due to gender and diurnal variation of this effect [55, 56]. In addition, there is some evidence of another deficiency of the HPA axis in various disorders associated with fatigue: hypofunction of corticotropin-releasing hormone-producing neurons (located in hypothalamus) [48, 59, 60]. Therefore, "exercising" the HPA system by repeated exposure to cold could potentially restore its normal function in CFS, or at least increase the net HPA activity (without a change in baseline activity [61]) and, possibly, reduce fatigue. For example, repeated cold stress has been shown to enhance HPA axis responsiveness to other stressors [62, 63] and to enhance cortisol responses to cold stress [64].

  2. 2)

    Cold hydrotherapy is known to produce a significant analgesic effect [6567], which could be beneficial in CFS, where pain symptoms are rather common [68, 69]. The cold stress-induced analgesia is believed to be mediated by increased production of opioid peptide beta-endorphin, which is an endogenous pain-killer [53, 55, 70, 71].

  3. 3)

    Exposure to cold is known to increase metabolic rate: for instance, head-out immersion in cold water of 20°C almost doubles metabolic rate, while at 14°C it is more than quadrupled [72]. Theoretically, the high metabolic rate may accelerate [73, 74] the process of recovery of muscle tissues from fatigue in CFS [24, 25, 75, 76] and some studies indeed show accelerated muscle recovery following immersion in cold water [77, 78]. In combination with cold-induced analgesia described above, the increased metabolic rate would be expected to reduce fatigue by both improving muscle recovery after exertion and by reducing muscle pain [79]. A cold-induced increase in cerebral metabolic rate [80] may also be consistent with reduced fatigue ([7, 81] contrary evidence: [82, 83]).

  4. 4)

    There is evidence that exposure to cold can activate some components of the brainstem arousal system [8486] (also known as the reticular activating system [87, 88]). In particular, cold stress appears to stimulate activity of serotonergic neurons of raphe nuclei [84, 8991] and noradrenergic neurons of locus ceruleus [84, 92], the situation that would be consistent with activation of behavior and enhanced somatomotor function of the brain [9, 87, 9396]. This could be beneficial in CFS because abnormally high fatigability of CFS patients appears to be mediated by a reduction in the ability of the CNS to generate motor neurotransmission [2123]. It is noteworthy that in polio survivors and patients with multiple sclerosis, the presence of minor lesions in the reticular activating system correlates with severe chronic fatigue [10, 97]. This kind of lesions can also cause lethargy in laboratory animals [9, 88, 98]. Reduced electrical activity in the reticular activating system also appears to correlate with fatigue in laboratory animals [99101]. At present, there is no evidence that CFS patients have lesions in the reticular activating system [9, 102], although there is some limited evidence of abnormalities of metabolism, blood flow, and electrical activity in the brainstem [81, 103105], the anatomical site of the reticular activating system [87, 88].

  5. 5)

    While the increased level of serotonin in the brainstem [85] is thought to correlate with arousal and increased cortical activity [11, 94, 106], high levels of serotonin in other areas of the brain, particularly in the hippocampus and frontal cortex, are believed to be associated with fatigue, which is the basis of "the serotonin hypothesis of central fatigue" [12, 13, 4145]. Whether high levels of brain serotonin actually cause fatigue or are merely an epiphenomenon is a subject of controversy [12, 13]. With respect to cold stress, studies suggest that it reduces the level of serotonin in most regions of the brain [107, 108] except the rostral brainstem [85], which would be consistent with diminished fatigue [12, 13] and could be beneficial in CFS ([3338], contrary evidence: [39, 40]).

  6. 6)

    Exposure to cold typically causes activation of the sympathetic nervous system (SNS) [49, 109], which, theoretically, can be undesirable in CFS because there is evidence of hyperactivity of some components of the SNS in CFS patients [18, 110]. It should be noted that physical exercise is also known to transiently activate the SNS [111] and graded exercise appears to be beneficial in CFS [112, 113]. Therefore, brief cold stress will not necessarily have adverse effects on CFS patients (more detailed discussion can be found in Additional file 1).

  1. 7)

    As described previously, brief cold hydrotherapy appears to be safe and does not seem to have either short-term or long-term adverse effects on health [109, 114117]. The effect of moderately cold hydrotherapy (16–23°C) on core body temperature is expected to be very small and therefore hypothermia is hardly a concern [118120].


Testing the hypothesis

To test the hypothesis, a treatment is proposed that consists of adapted cold showers (20°C, 3 minutes, preceded by 5-minute gradual adaptation) twice a day. The detailed study protocol can be found in Additional file 2. Statistically insignificant preliminary evidence is described in Additional file 3.

Implications of the hypothesis

If statistically significant studies confirm (or refute) the hypothesis, this could further our understanding of the mechanisms of physiological fatigue and possibly contribute to the development of new therapeutic approaches to CFS.



The author thanks Daniel Gebreselassie, Ph.D., for providing critical comments about the manuscript. Funding for this work was in part derived from the Children's National Medical Center/George Washington University Fellowship, Washington, DC, USA.

Authors’ Affiliations

Molecular Radiobiology Section, the Department of Radiation Oncology, Virginia Commonwealth University School of Medicine, 401 College St, Richmond, VA 23298, USA


  1. Weir JP, Beck TW, Cramer JT, Housh TJ: Is fatigue all in your head? A critical review of the central governor model. Br J Sports Med. 2006, 40 (7): 573-86; discussion 586. 10.1136/bjsm.2005.023028.PubMed CentralPubMedView ArticleGoogle Scholar
  2. Gandevia SC: Some central and peripheral factors affecting human motoneuronal output in neuromuscular fatigue. Sports Med. 1992, 13 (2): 93-98.PubMedView ArticleGoogle Scholar
  3. Guessous I, Favrat B, Cornuz J, Verdon F: Fatigue: review and systematic approach to potential causes. Rev Med Suisse. 2006, 2 (89): 2725-2731.PubMedGoogle Scholar
  4. Evans WJ, Lambert CP: Physiological basis of fatigue. Am J Phys Med Rehabil. 2007, 86 (1 Suppl): S29-46. 10.1097/PHM.0b013e31802ba53c.PubMedView ArticleGoogle Scholar
  5. Schillings ML, Kalkman JS, Janssen HM, van Engelen BG, Bleijenberg G, Zwarts MJ: Experienced and physiological fatigue in neuromuscular disorders. Clin Neurophysiol. 2007, 118 (2): 292-300. 10.1016/j.clinph.2006.10.018.PubMedView ArticleGoogle Scholar
  6. Shulman RG, Rothman DL: The "glycogen shunt" in exercising muscle: A role for glycogen in muscle energetics and fatigue. Proc Natl Acad Sci U S A. 2001, 98 (2): 457-461. 10.1073/pnas.98.2.457.PubMed CentralPubMedView ArticleGoogle Scholar
  7. Dalsgaard MK, Secher NH: The brain at work: A cerebral metabolic manifestation of central fatigue?. J Neurosci Res. 2007, 85 (15): 3334-9. 10.1002/jnr.21274.PubMedView ArticleGoogle Scholar
  8. Gandevia SC: Spinal and supraspinal factors in human muscle fatigue. Physiol Rev. 2001, 81 (4): 1725-1789.PubMedGoogle Scholar
  9. Dickinson CJ: Chronic fatigue syndrome--aetiological aspects. Eur J Clin Invest. 1997, 27 (4): 257-267. 10.1046/j.1365-2362.1997.1120664.x.PubMedView ArticleGoogle Scholar
  10. Staub F, Bogousslavsky J: Fatigue after stroke: a major but neglected issue. Cerebrovasc Dis. 2001, 12 (2): 75-81. 10.1159/000047685.PubMedView ArticleGoogle Scholar
  11. Sandyk R: Treatment with weak electromagnetic fields improves fatigue associated with multiple sclerosis. Int J Neurosci. 1996, 84 (1-4): 177-186. 10.3109/00207459608987263.PubMedView ArticleGoogle Scholar
  12. Meeusen R, Watson P, Hasegawa H, Roelands B, Piacentini MF: Central fatigue: the serotonin hypothesis and beyond. Sports Med. 2006, 36 (10): 881-909. 10.2165/00007256-200636100-00006.PubMedView ArticleGoogle Scholar
  13. Blomstrand E: A role for branched-chain amino acids in reducing central fatigue. J Nutr. 2006, 136 (2): 544S-547S.PubMedGoogle Scholar
  14. Chronic fatigue syndrome: basic facts. Centers for Disease Control and Prevention, Atlanta, GA, USA.
  15. Cho HJ, Skowera A, Cleare A, Wessely S: Chronic fatigue syndrome: an update focusing on phenomenology and pathophysiology. Curr Opin Psychiatry. 2006, 19 (1): 67-73. 10.1097/01.yco.0000194370.40062.b0.PubMedView ArticleGoogle Scholar
  16. Chronic fatigue syndrome: possible causes. Centers for Disease Control and Prevention, Atlanta, GA, USA.
  17. Cleare AJ: The neuroendocrinology of chronic fatigue syndrome. Endocr Rev. 2003, 24 (2): 236-252.PubMedView ArticleGoogle Scholar
  18. Freeman R, Komaroff AL: Does the chronic fatigue syndrome involve the autonomic nervous system?. Am J Med. 1997, 102 (4): 357-364. 10.1016/S0002-9343(97)00087-9.PubMedView ArticleGoogle Scholar
  19. Chronic fatigue syndrome: Treatment options. Centers for Disease Control and Prevention, Atlanta, GA, USA.
  20. Peterson PK, Pheley A, Schroeppel J, Schenck C, Marshall P, Kind A, Haugland JM, Lambrecht LJ, Swan S, Goldsmith S: A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome. Arch Intern Med. 1998, 158 (8): 908-914. 10.1001/archinte.158.8.908.PubMedView ArticleGoogle Scholar
  21. Schillings ML, Kalkman JS, van der Werf SP, van Engelen BG, Bleijenberg G, Zwarts MJ: Diminished central activation during maximal voluntary contraction in chronic fatigue syndrome. Clin Neurophysiol. 2004, 115 (11): 2518-2524. 10.1016/j.clinph.2004.06.007.PubMedView ArticleGoogle Scholar
  22. Siemionow V, Fang Y, Calabrese L, Sahgal V, Yue GH: Altered central nervous system signal during motor performance in chronic fatigue syndrome. Clin Neurophysiol. 2004, 115 (10): 2372-2381.PubMedView ArticleGoogle Scholar
  23. Kent-Braun JA, Sharma KR, Weiner MW, Massie B, Miller RG: Central basis of muscle fatigue in chronic fatigue syndrome. Neurology. 1993, 43 (1): 125-131.PubMedView ArticleGoogle Scholar
  24. Wong R, Lopaschuk G, Zhu G, Walker D, Catellier D, Burton D, Teo K, Collins-Nakai R, Montague T: Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest. 1992, 102 (6): 1716-1722. 10.1378/chest.102.6.1716.PubMedView ArticleGoogle Scholar
  25. Jammes Y, Steinberg JG, Mambrini O, Bregeon F, Delliaux S: Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med. 2005, 257 (3): 299-310. 10.1111/j.1365-2796.2005.01452.x.PubMedView ArticleGoogle Scholar
  26. McCully KK, Smith S, Rajaei S, Leigh JS, Natelson BH: Blood flow and muscle metabolism in chronic fatigue syndrome. Clin Sci (Lond). 2003, 104 (6): 641-647.View ArticleGoogle Scholar
  27. Scott LV, Burnett F, Medbak S, Dinan TG: Naloxone-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Psychol Med. 1998, 28 (2): 285-293. 10.1017/S0033291797006260.PubMedView ArticleGoogle Scholar
  28. Conti F, Pittoni V, Sacerdote P, Priori R, Meroni PL, Valesini G: Decreased immunoreactive beta-endorphin in mononuclear leucocytes from patients with chronic fatigue syndrome. Clin Exp Rheumatol. 1998, 16 (6): 729-732.PubMedGoogle Scholar
  29. Panerai AE, Vecchiet J, Panzeri P, Meroni P, Scarone S, Pizzigallo E, Giamberardino MA, Sacerdote P: Peripheral blood mononuclear cell beta-endorphin concentration is decreased in chronic fatigue syndrome and fibromyalgia but not in depression: preliminary report. Clin J Pain. 2002, 18 (4): 270-273. 10.1097/00002508-200207000-00008.PubMedView ArticleGoogle Scholar
  30. Parker AJ, Wessely S, Cleare AJ: The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol Med. 2001, 31 (8): 1331-1345.PubMedView ArticleGoogle Scholar
  31. Inder WJ, Prickett TC, Mulder RT: Normal opioid tone and hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome despite marked functional impairment. Clin Endocrinol (Oxf). 2005, 62 (3): 343-348. 10.1111/j.1365-2265.2005.02220.x.View ArticleGoogle Scholar
  32. Prieto J, Subira ML, Castilla A, Serrano M: Naloxone-reversible monocyte dysfunction in patients with chronic fatigue syndrome. Scand J Immunol. 1989, 30 (1): 13-20. 10.1111/j.1365-3083.1989.tb01183.x.PubMedView ArticleGoogle Scholar
  33. Cleare AJ, Bearn J, Allain T, McGregor A, Wessely S, Murray RM, O'Keane V: Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord. 1995, 34 (4): 283-289. 10.1016/0165-0327(95)00026-J.PubMedView ArticleGoogle Scholar
  34. Bakheit AM, Behan PO, Dinan TG, Gray CE, O'Keane V: Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. BMJ. 1992, 304 (6833): 1010-1012.PubMed CentralPubMedView ArticleGoogle Scholar
  35. Sharpe M, Hawton K, Clements A, Cowen PJ: Increased brain serotonin function in men with chronic fatigue syndrome. BMJ. 1997, 315 (7101): 164-165.PubMed CentralPubMedView ArticleGoogle Scholar
  36. Spath M, Welzel D, Farber L: Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results. Scand J Rheumatol Suppl. 2000, 113: 72-77.PubMedView ArticleGoogle Scholar
  37. Badawy AA, Morgan CJ, Llewelyn MB, Albuquerque SR, Farmer A: Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome. J Psychopharmacol. 2005, 19 (4): 385-391. 10.1177/0269881105053293.PubMedView ArticleGoogle Scholar
  38. Georgiades E, Behan WM, Kilduff LP, Hadjicharalambous M, Mackie EE, Wilson J, Ward SA, Pitsiladis YP: Chronic fatigue syndrome: new evidence for a central fatigue disorder. Clin Sci (Lond). 2003, 105 (2): 213-218.View ArticleGoogle Scholar
  39. Yatham LN, Morehouse RL, Chisholm BT, Haase DA, MacDonald DD, Marrie TJ: Neuroendocrine assessment of serotonin (5-HT) function in chronic fatigue syndrome. Can J Psychiatry. 1995, 40 (2): 93-96.PubMedGoogle Scholar
  40. Vassallo CM, Feldman E, Peto T, Castell L, Sharpley AL, Cowen PJ: Decreased tryptophan availability but normal post-synaptic 5-HT2c receptor sensitivity in chronic fatigue syndrome. Psychol Med. 2001, 31 (4): 585-591. 10.1017/S0033291701003580.PubMedView ArticleGoogle Scholar
  41. Romanowski W, Grabiec S: The role of serotonin in the mechanism of central fatigue. Acta Physiol Pol. 1974, 25 (2): 127-134.PubMedGoogle Scholar
  42. Soares DD, Coimbra CC, Marubayashi U: Tryptophan-induced central fatigue in exercising rats is related to serotonin content in preoptic area. Neurosci Lett. 2007, 415 (3): 274-278. 10.1016/j.neulet.2007.01.035.PubMedView ArticleGoogle Scholar
  43. Fernstrom JD, Fernstrom MH: Exercise, serum free tryptophan, and central fatigue. J Nutr. 2006, 136 (2): 553S-559S.PubMedGoogle Scholar
  44. Davis JM: Carbohydrates, branched-chain amino acids, and endurance: the central fatigue hypothesis. Int J Sport Nutr. 1995, 5 Suppl: S29-38.PubMedGoogle Scholar
  45. Low D, Cable T, Purvis A: Exercise thermoregulation and hyperprolactinaemia. Ergonomics. 2005, 48 (11-14): 1547-1557. 10.1080/00140130500101387.PubMedView ArticleGoogle Scholar
  46. Arumugam TV, Gleichmann M, Tang SC, Mattson MP: Hormesis/preconditioning mechanisms, the nervous system and aging. Ageing Res Rev. 2006, 5 (2): 165-178. 10.1016/j.arr.2006.03.003.PubMedView ArticleGoogle Scholar
  47. Leslie M: How can we use moderate stresses to fortify humans and slow aging?. Sci Aging Knowledge Environ. 2005, 2005 (26): nf49-10.1126/sageke.2005.26.nf49.PubMedGoogle Scholar
  48. Swain MG: Fatigue in chronic disease. Clin Sci (Lond). 2000, 99 (1): 1-8.View ArticleGoogle Scholar
  49. Nakamoto M: Responses of sympathetic nervous system to cold exposure in vibration syndrome subjects and age-matched healthy controls. Int Arch Occup Environ Health. 1990, 62 (2): 177-181. 10.1007/BF00383595.PubMedView ArticleGoogle Scholar
  50. Nakane T, Audhya T, Kanie N, Hollander CS: Evidence for a role of endogenous corticotropin-releasing factor in cold, ether, immobilization, and traumatic stress. Proc Natl Acad Sci U S A. 1985, 82 (4): 1247-1251. 10.1073/pnas.82.4.1247.PubMed CentralPubMedView ArticleGoogle Scholar
  51. Ohno H, Yahata T, Yamashita K, Kuroshima A: Effect of acute cold exposure on ACTH and zinc concentrations in human plasma. Jpn J Physiol. 1987, 37 (4): 749-755. 10.2170/jjphysiol.37.749.PubMedView ArticleGoogle Scholar
  52. Goundasheva D, Andonova M, Ivanov V: Changes in some parameters of the immune response in rats after cold stress. Zentralbl Veterinarmed B. 1994, 41 (10): 670-674.PubMedGoogle Scholar
  53. Vaswani KK, Richard CW, Tejwani GA: Cold swim stress-induced changes in the levels of opioid peptides in the rat CNS and peripheral tissues. Pharmacol Biochem Behav. 1988, 29 (1): 163-168. 10.1016/0091-3057(88)90290-0.PubMedView ArticleGoogle Scholar
  54. Giagnoni G, Santagostino A, Senini R, Fumagalli P, Gori E: Cold stress in the rat induces parallel changes in plasma and pituitary levels of endorphin and ACTH. Pharmacol Res Commun. 1983, 15 (1): 15-21. 10.1016/S0031-6989(83)80076-9.PubMedView ArticleGoogle Scholar
  55. Gerra G, Volpi R, Delsignore R, Maninetti L, Caccavari R, Vourna S, Maestri D, Chiodera P, Ugolotti G, Coiro V: Sex-related responses of beta-endorphin, ACTH, GH and PRL to cold exposure in humans. Acta Endocrinol (Copenh). 1992, 126 (1): 24-28.Google Scholar
  56. Smith DJ, Deuster PA, Ryan CJ, Doubt TJ: Prolonged whole body immersion in cold water: hormonal and metabolic changes. Undersea Biomed Res. 1990, 17 (2): 139-147.PubMedGoogle Scholar
  57. Koska J, Ksinantova L, Sebokova E, Kvetnansky R, Klimes I, Chrousos G, Pacak K: Endocrine regulation of subcutaneous fat metabolism during cold exposure in humans. Ann N Y Acad Sci. 2002, 967: 500-505.PubMedView ArticleGoogle Scholar
  58. Marino F, Sockler JM, Fry JM: Thermoregulatory, metabolic and sympathoadrenal responses to repeated brief exposure to cold. Scand J Clin Lab Invest. 1998, 58 (7): 537-545. 10.1080/00365519850186157.PubMedView ArticleGoogle Scholar
  59. Gold PW, Licinio J, Wong ML, Chrousos GP: Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N Y Acad Sci. 1995, 771: 716-729. 10.1111/j.1749-6632.1995.tb44723.x.PubMedView ArticleGoogle Scholar
  60. Neeck G, Crofford LJ: Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am. 2000, 26 (4): 989-1002. 10.1016/S0889-857X(05)70180-0.PubMedView ArticleGoogle Scholar
  61. Dorfman M, Arancibia S, Fiedler JL, Lara HE: Chronic intermittent cold stress activates ovarian sympathetic nerves and modifies ovarian follicular development in the rat. Biol Reprod. 2003, 68 (6): 2038-2043. 10.1095/biolreprod.102.008318.PubMedView ArticleGoogle Scholar
  62. Pardon MC, Ma S, Morilak DA: Chronic cold stress sensitizes brain noradrenergic reactivity and noradrenergic facilitation of the HPA stress response in Wistar Kyoto rats. Brain Res. 2003, 971 (1): 55-65. 10.1016/S0006-8993(03)02355-2.PubMedView ArticleGoogle Scholar
  63. Ma S, Morilak DA: Chronic intermittent cold stress sensitises the hypothalamic-pituitary-adrenal response to a novel acute stress by enhancing noradrenergic influence in the rat paraventricular nucleus. J Neuroendocrinol. 2005, 17 (11): 761-769. 10.1111/j.1365-2826.2005.01372.x.PubMedView ArticleGoogle Scholar
  64. Dugue B, Leppanen E: Adaptation related to cytokines in man: effects of regular swimming in ice-cold water. Clin Physiol. 2000, 20 (2): 114-121. 10.1046/j.1365-2281.2000.00235.x.PubMedView ArticleGoogle Scholar
  65. Truesdell LS, Bodnar RJ: Reduction in cold-water swim analgesia following hypothalamic paraventricular nucleus lesions. Physiol Behav. 1987, 39 (6): 727-731. 10.1016/0031-9384(87)90257-5.PubMedView ArticleGoogle Scholar
  66. Kenunen OG, Prakh'e IV, Kozlovskii BL: A change in the alarm level entails a change in behavioural strategy of mice in stress and a change in analgesia induced by it. Ross Fiziol Zh Im I M Sechenova. 2004, 90 (12): 1555-1562.PubMedGoogle Scholar
  67. LaFoy J, Geden EA: Postepisiotomy pain: warm versus cold sitz bath. J Obstet Gynecol Neonatal Nurs. 1989, 18 (5): 399-403. 10.1111/j.1552-6909.1989.tb00493.x.PubMedView ArticleGoogle Scholar
  68. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A: The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994, 121 (12): 953-959.PubMedView ArticleGoogle Scholar
  69. Meeus M, Nijs J: Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol. 2007, 26 (4): 465-473. 10.1007/s10067-006-0433-9.PubMed CentralPubMedView ArticleGoogle Scholar
  70. Glickman-Weiss EL, Nelson AG, Hearon CM, Goss FL, Robertson RJ: Are beta-endorphins and thermoregulation during cold-water immersion related?. Undersea Hyperb Med. 1993, 20 (3): 205-213.PubMedGoogle Scholar
  71. Pickar D, Davis GC, Schulz SC, Extein I, Wagner R, Naber D, Gold PW, van Kammen DP, Goodwin FK, Wyatt RJ, Li CH, Bunney WE: Behavioral and biological effects of acute beta-endorphin injection in schizophrenic and depressed patients. Am J Psychiatry. 1981, 138 (2): 160-166.PubMedView ArticleGoogle Scholar
  72. Sramek P, Simeckova M, Jansky L, Savlikova J, Vybiral S: Human physiological responses to immersion into water of different temperatures. Eur J Appl Physiol. 2000, 81 (5): 436-442. 10.1007/s004210050065.PubMedView ArticleGoogle Scholar
  73. St Rose JE, Murray GW, Howe SA: Effect of alterations in metabolic rate on the duration of tolerance in neonatally injected animals. Int Arch Allergy Appl Immunol. 1976, 52 (1-4): 183-187.PubMedView ArticleGoogle Scholar
  74. Vallerand AL, Zamecnik J, Jacobs I: Plasma glucose turnover during cold stress in humans. J Appl Physiol. 1995, 78 (4): 1296-1302.PubMedGoogle Scholar
  75. McCully KK, Natelson BH: Impaired oxygen delivery to muscle in chronic fatigue syndrome. Clin Sci (Lond). 1999, 97 (5): 603-8; discussion 611-3.View ArticleGoogle Scholar
  76. Fulle S, Mecocci P, Fano G, Vecchiet I, Vecchini A, Racciotti D, Cherubini A, Pizzigallo E, Vecchiet L, Senin U, Beal MF: Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med. 2000, 29 (12): 1252-1259. 10.1016/S0891-5849(00)00419-6.PubMedView ArticleGoogle Scholar
  77. Nomura T, Kawano F, Kang MS, Lee JH, Han EY, Kim CK, Sato Y, Ohira Y: Effects of long-term cold exposure on contractile muscles of rats. Jpn J Physiol. 2002, 52 (1): 85-93. 10.2170/jjphysiol.52.85.PubMedView ArticleGoogle Scholar
  78. Yanagisawa O, Niitsu M, Yoshioka H, Goto K, Kudo H, Itai Y: The use of magnetic resonance imaging to evaluate the effects of cooling on skeletal muscle after strenuous exercise. Eur J Appl Physiol. 2003, 89 (1): 53-62. 10.1007/s00421-002-0749-3.PubMedView ArticleGoogle Scholar
  79. Cook DB, Nagelkirk PR, Poluri A, Mores J, Natelson BH: The influence of aerobic fitness and fibromyalgia on cardiorespiratory and perceptual responses to exercise in patients with chronic fatigue syndrome. Arthritis Rheum. 2006, 54 (10): 3351-3362. 10.1002/art.22124.PubMedView ArticleGoogle Scholar
  80. Szelenyi Z, Donhoffer Z: The effect of cold exposure on cerebral blood flow and cerebral available oxygen (aO2) in the rat and rabbit: thermoregulatory heat production by the brain and the possible role of neuroglia. Acta Physiol Acad Sci Hung. 1978, 52 (4): 391-402.PubMedGoogle Scholar
  81. Tirelli U, Chierichetti F, Tavio M, Simonelli C, Bianchin G, Zanco P, Ferlin G: Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. Am J Med. 1998, 105 (3A): 54S-58S. 10.1016/S0002-9343(98)00179-X.PubMedView ArticleGoogle Scholar
  82. Abu-Judeh HH, Levine S, Kumar M, el-Zeftawy H, Naddaf S, Lou JQ, Abdel-Dayem HM: Comparison of SPET brain perfusion and 18F-FDG brain metabolism in patients with chronic fatigue syndrome. Nucl Med Commun. 1998, 19 (11): 1065-1071.PubMedView ArticleGoogle Scholar
  83. Siessmeier T, Nix WA, Hardt J, Schreckenberger M, Egle UT, Bartenstein P: Observer independent analysis of cerebral glucose metabolism in patients with chronic fatigue syndrome. J Neurol Neurosurg Psychiatry. 2003, 74 (7): 922-928. 10.1136/jnnp.74.7.922.PubMed CentralPubMedView ArticleGoogle Scholar
  84. Yuan L, Brewer C, Pfaff D: Immediate-early Fos protein levels in brainstem neurons of male and female gonadectomized mice subjected to cold exposure. Stress. 2002, 5 (4): 285-294.PubMedView ArticleGoogle Scholar
  85. Passerin AM, Bellush LL, Henley WN: Activation of bulbospinal serotonergic neurons during cold exposure. Can J Physiol Pharmacol. 1999, 77 (4): 250-258. 10.1139/cjpp-77-4-250.PubMedView ArticleGoogle Scholar
  86. Baffi JS, Palkovits M: Fine topography of brain areas activated by cold stress. A fos immunohistochemical study in rats. Neuroendocrinology. 2000, 72 (2): 102-113. 10.1159/000054577.PubMedView ArticleGoogle Scholar
  87. Kayama Y, Ito S, Koyama Y, Jodo E: Tonic and phasic components of the ascending reticular activating system. Fukushima J Med Sci. 1991, 37 (2): 59-74.PubMedGoogle Scholar
  88. Siegel J: Brain mechanisms that control sleep and waking. Naturwissenschaften. 2004, 91 (8): 355-365. 10.1007/s00114-004-0541-9.PubMedGoogle Scholar
  89. Dickenson AH: Specific responses of rat raphe neurones to skin temperature. J Physiol. 1977, 273 (1): 277-293.PubMed CentralPubMedView ArticleGoogle Scholar
  90. McAllen RM, Farrell M, Johnson JM, Trevaks D, Cole L, McKinley MJ, Jackson G, Denton DA, Egan GF: Human medullary responses to cooling and rewarming the skin: a functional MRI study. Proc Natl Acad Sci U S A. 2006, 103 (3): 809-813. 10.1073/pnas.0509862103.PubMed CentralPubMedView ArticleGoogle Scholar
  91. Ootsuka Y, Blessing WW: Inhibition of medullary raphe/parapyramidal neurons prevents cutaneous vasoconstriction elicited by alerting stimuli and by cold exposure in conscious rabbits. Brain Res. 2005, 1051 (1-2): 189-193. 10.1016/j.brainres.2005.05.062.PubMedView ArticleGoogle Scholar
  92. Jiang XH, Guo SY, Xu S, Yin QZ, Ohshita Y, Naitoh M, Horibe Y, Hisamitsu T: Sympathetic nervous system mediates cold stress-induced suppression of natural killer cytotoxicity in rats. Neurosci Lett. 2004, 358 (1): 1-4. 10.1016/j.neulet.2003.11.007.PubMedView ArticleGoogle Scholar
  93. Stone EA, Lin Y, Ahsan R, Quartermain D: Role of locus coeruleus alpha1-adrenoceptors in motor activity in rats. Synapse. 2004, 54 (3): 164-172. 10.1002/syn.20074.PubMedView ArticleGoogle Scholar
  94. Lovick TA: The medullary raphe nuclei: a system for integration and gain control in autonomic and somatomotor responsiveness?. Exp Physiol. 1997, 82 (1): 31-41.PubMedView ArticleGoogle Scholar
  95. Kiyashchenko LI, Mileykovskiy BY, Lai YY, Siegel JM: Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. J Neurophysiol. 2001, 85 (5): 2008-2016.PubMedGoogle Scholar
  96. Hornung JP: The human raphe nuclei and the serotonergic system. J Chem Neuroanat. 2003, 26 (4): 331-343. 10.1016/j.jchemneu.2003.10.002.PubMedView ArticleGoogle Scholar
  97. Bruno RL, Cohen JM, Galski T, Frick NM: The neuroanatomy of post-polio fatigue. Arch Phys Med Rehabil. 1994, 75 (5): 498-504.PubMedGoogle Scholar
  98. Szymusiak R, Iriye T, McGinty D: Sleep-waking discharge of neurons in the posterior lateral hypothalamic area of cats. Brain Res Bull. 1989, 23 (1-2): 111-120. 10.1016/0361-9230(89)90169-X.PubMedView ArticleGoogle Scholar
  99. Derevenco P, Stoica N, Sovrea I, Imreh S: Central and peripheral effects of 6-hydroxydopamine on exercise performance in rats. Psychoneuroendocrinology. 1986, 11 (2): 141-153. 10.1016/0306-4530(86)90049-1.PubMedView ArticleGoogle Scholar
  100. Boev VM, Krauz VA: Functional state of the hippocampo-reticular complex during submaximal physical loading and fatigue. Zh Vyssh Nerv Deiat Im I P Pavlova. 1981, 31 (5): 1029-1037.PubMedGoogle Scholar
  101. Fornal CA, Martin-Cora FJ, Jacobs BL: "Fatigue" of medullary but not mesencephalic raphe serotonergic neurons during locomotion in cats. Brain Res. 2006, 1072 (1): 55-61. 10.1016/j.brainres.2005.12.007.PubMedView ArticleGoogle Scholar
  102. Lewis DH, Mayberg HS, Fischer ME, Goldberg J, Ashton S, Graham MM, Buchwald D: Monozygotic twins discordant for chronic fatigue syndrome: regional cerebral blood flow SPECT. Radiology. 2001, 219 (3): 766-773.PubMedView ArticleGoogle Scholar
  103. Neri G, Bianchedi M, Croce A, Moretti A: "Prolonged" decay test and auditory brainstem responses in the clinical diagnosis of the chronic fatigue syndrome. Acta Otorhinolaryngol Ital. 1996, 16 (4): 317-323.PubMedGoogle Scholar
  104. Bianchedi M, Croce A, Moretti A, Neri G, Barberio A, Iezzi A, Pizzigallo E: Auditory brain stem evoked potentials in the evaluation of chronic fatigue syndrome. Acta Otorhinolaryngol Ital. 1995, 15 (6): 403-410.PubMedGoogle Scholar
  105. Costa DC, Tannock C, Brostoff J: Brainstem perfusion is impaired in chronic fatigue syndrome. QJM. 1995, 88 (11): 767-773.PubMedGoogle Scholar
  106. O'Leary OF, Bechtholt AJ, Crowley JJ, Valentino RJ, Lucki I: The role of noradrenergic tone in the dorsal raphe nucleus of the mouse in the acute behavioral effects of antidepressant drugs. Eur Neuropsychopharmacol. 2007, 17 (3): 215-226. 10.1016/j.euroneuro.2006.06.012.PubMedView ArticleGoogle Scholar
  107. Aly MS, Mohamed MI, Rahman TA, Moustafa S: Studies of contents of norepinephrine and 5-hydroxytryptamine in brain--I. Normal and cold exposure. Comp Biochem Physiol C. 1985, 82 (1): 155-158. 10.1016/0742-8413(85)90223-3.PubMedView ArticleGoogle Scholar
  108. Toh CC: Effects of temperature on the 5-hydroxytryptamine (serotonin) content of tissues. J Physiol. 1960, 151: 410-415.PubMed CentralPubMedView ArticleGoogle Scholar
  109. Jansky L, Sramek P, Savlikova J, Ulicny B, Janakova H, Horky K: Change in sympathetic activity, cardiovascular functions and plasma hormone concentrations due to cold water immersion in men. Eur J Appl Physiol Occup Physiol. 1996, 74 (1-2): 148-152. 10.1007/BF00376507.PubMedView ArticleGoogle Scholar
  110. Wyller VB, Godang K, Morkrid L, Saul JP, Thaulow E, Walloe L: Abnormal thermoregulatory responses in adolescents with chronic fatigue syndrome: relation to clinical symptoms. Pediatrics. 2007, 120 (1): e129-37. 10.1542/peds.2006-2759.PubMedView ArticleGoogle Scholar
  111. Toth MJ, Gardner AW, Arciero PJ, Calles-Escandon J, Poehlman ET: Gender differences in fat oxidation and sympathetic nervous system activity at rest and during submaximal exercise in older individuals. Clin Sci (Lond). 1998, 95 (1): 59-66.View ArticleGoogle Scholar
  112. Moss-Morris R, Sharon C, Tobin R, Baldi JC: A randomized controlled graded exercise trial for chronic fatigue syndrome: outcomes and mechanisms of change. J Health Psychol. 2005, 10 (2): 245-259. 10.1177/1359105305049774.PubMedView ArticleGoogle Scholar
  113. Wallman KE, Morton AR, Goodman C, Grove R, Guilfoyle AM: Randomised controlled trial of graded exercise in chronic fatigue syndrome. Med J Aust. 2004, 180 (9): 444-448.PubMedGoogle Scholar
  114. Holloszy JO, Smith EK: Longevity of cold-exposed rats: a reevaluation of the "rate-of-living theory". J Appl Physiol. 1986, 61 (5): 1656-1660.PubMedGoogle Scholar
  115. Jansky L, Pospisilova D, Honzova S, Ulicny B, Sramek P, Zeman V, Kaminkova J: Immune system of cold-exposed and cold-adapted humans. Eur J Appl Physiol Occup Physiol. 1996, 72 (5-6): 445-450. 10.1007/BF00242274.PubMedView ArticleGoogle Scholar
  116. Castellani JW, IK MB, Rhind SG: Cold exposure: human immune responses and intracellular cytokine expression. Med Sci Sports Exerc. 2002, 34 (12): 2013-2020. 10.1097/00005768-200212000-00023.PubMedView ArticleGoogle Scholar
  117. Banerjee SK, Aviles H, Fox MT, Monroy FP: Cold stress-induced modulation of cell immunity during acute Toxoplasma gondii infection in mice. J Parasitol. 1999, 85 (3): 442-447. 10.2307/3285776.PubMedView ArticleGoogle Scholar
  118. Doufas AG, Sessler DI: Physiology and clinical relevance of induced hypothermia. Neurocrit Care. 2004, 1 (4): 489-498. 10.1385/NCC:1:4:489.PubMedView ArticleGoogle Scholar
  119. Tikuisis P: Heat balance precedes stabilization of body temperatures during cold water immersion. J Appl Physiol. 2003, 95 (1): 89-96.PubMedView ArticleGoogle Scholar
  120. McCullough L, Arora S: Diagnosis and treatment of hypothermia. Am Fam Physician. 2004, 70 (12): 2325-2332. Scholar


© Shevchuk; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.